Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 30;25(19):10570.
doi: 10.3390/ijms251910570.

Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma

Allison R Valerius  1 , Lauren M Webb  1 , Anna Thomsen  1 , Eric J Lehrer  2 , William G Breen  2 , Jian L Campian  3 , Cecile Riviere-Cazaux  4 , Terry C Burns  4 , Ugur Sener  1   3
Affiliations
Review

Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma

Allison R Valerius et al. Int J Mol Sci. .

Abstract

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite an established standard of care including surgical resection, radiation therapy, and chemotherapy, GBM unfortunately is associated with a dismal prognosis. Therefore, researchers are extensively evaluating avenues to expand GBM therapy and improve outcomes in patients with GBM. In this review, we provide a broad overview of novel GBM therapies that have recently completed or are actively undergoing study in clinical trials. These therapies expand across medical, surgical, and radiation clinical trials. We additionally review methods for improving clinical trial design in GBM.

Keywords: glioblastoma; high-grade glioma; immunotherapy; radiation therapy; review of therapy; surgical therapy; targeted molecular therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ostrom Q.T., Price M., Neff C., Cioffi G., Waite K.A., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019. Neuro Oncol. 2022;24:v1–v95. doi: 10.1093/neuonc/noac202. - DOI - PMC - PubMed
    1. Stupp R., Taillibert S., Kanner A., Read W., Steinberg D., Lhermitte B., Toms S., Idbaih A., Ahluwalia M.S., Fink K., et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318:2306–2316. doi: 10.1001/jama.2017.18718. - DOI - PMC - PubMed
    1. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005;352:997–1003. doi: 10.1056/NEJMoa043331. - DOI - PubMed
    1. Hovey E.J., Field K.M., Rosenthal M.A., Barnes E.H., Cher L., Nowak A.K., Wheeler H., Sawkins K., Livingstone A., Phal P., et al. Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: An exploratory randomized phase II trial. Neurooncol. Pract. 2017;4:171–181. doi: 10.1093/nop/npw025. - DOI - PMC - PubMed
    1. Perry J.R., Bélanger K., Mason W.P., Fulton D., Kavan P., Easaw J., Shields C., Kirby S., Macdonald D.R., Eisenstate D.D., et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J. Clin. Oncol. 2010;28:2051–2057. doi: 10.1200/JCO.2009.26.5520. - DOI - PubMed

LinkOut - more resources